{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"59","upperLimit":"90","value":"77"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"}],"units":"Participants"}],"description":"Platelet Engraftment rate was defined as the number of participants that received an engraftment within 1 year post-transplant and the platelets \\>= 20 x 10\\^9/L after 7 consecutive days with no platelet transfusions, out of the total number of participants. The rate was computed with corresponding exact 95% confidence intervals based on the methodology of Clopper and Pearson.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 2 hours on days -6 and -5. Patients undergo TBI on days -1 and PBSCT on day 0.\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPeripheral Blood Stem Cell Transplantation: Undergo PBSCT\n\nTotal-Body Irradiation: Undergo TBI","id":"OG000","title":"Treatment (Fludarabine, Cyclophosphamide, TBI, PBSCT)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"At 1 year post-transplant","title":"Platelet Engraftment Rate, the Percentage of Participants That Had a Successful Engraftment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}